Zobrazeno 1 - 10
of 1 816
pro vyhledávání: '"Michael L Johnson"'
Autor:
Jarzyna, Luke
Publikováno v:
Black Scholar. Jul-Oct2023, Vol. 53 Issue 3/4, p43-50. 8p.
Autor:
Mantasha Tabassum, Soumya G. Chikermane, Camille Johnson, Noor M. Abdulkareem, Elisabeth M. Wang, Michael L. Johnson, Meghana V. Trivedi
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Background Cardiovascular (CV) disease is a leading cause of death in breast cancer (BC) patients due to the increased age and treatments. While individual β-blockers have been investigated to manage CV complications, various β-blockers ha
Externí odkaz:
https://doaj.org/article/d68bdaebd5e34cefa3a68098abf8e26f
Autor:
Reeve, W. Paul
Publikováno v:
The Historian, 2009 Apr 01. 71(1), 116-117.
Externí odkaz:
https://www.jstor.org/stable/24454180
Autor:
Herron, John
Publikováno v:
Western Historical Quarterly, 2008 Oct 01. 39(3), 353-354.
Externí odkaz:
https://www.jstor.org/stable/25443738
Autor:
Farmer, Jared
Publikováno v:
Environmental History, 2008 Jul 01. 13(3), 578-579.
Externí odkaz:
https://www.jstor.org/stable/25473278
Autor:
Crook, Nathan C.
Publikováno v:
Western American Literature, 2008 Apr 01. 43(1), 92-93.
Externí odkaz:
https://www.jstor.org/stable/43025132
Autor:
Righter, Robert W.
Publikováno v:
The American Historical Review, 2008 Feb 01. 113(1), 189-190.
Externí odkaz:
https://www.jstor.org/stable/40007362
Autor:
Bishop, James E.
Publikováno v:
Interdisciplinary Studies in Literature and Environment, 2008 Jan 01. 15(1), 270-272.
Externí odkaz:
https://www.jstor.org/stable/44086696
Autor:
Coleman, Jon
Publikováno v:
Montana: The Magazine of Western History, 2007 Oct 01. 57(3), 73-73.
Externí odkaz:
https://www.jstor.org/stable/25485640
Autor:
Ravi K. Goyal, Sean D. Candrilli, Susan Abughosh, Hua Chen, Holly M. Holmes, Michael L. Johnson
Publikováno v:
Cancers, Vol 16, Iss 12, p 2168 (2024)
In hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC), cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) have replaced endocrine therapy alone as the standard of care; however, sev
Externí odkaz:
https://doaj.org/article/b6620fc8e52f4f608fa17c59d2663bfd